熱門資訊> 正文
SCHMID集团报告第二季度收入为2770万欧元;全年订单目标增至1.25亿至1.5亿欧元
2026-07-15 15:53
- SCHMID Group N.V. press release (SHMD): Q2 Revenue of €27.7M.
- In the second quarter of 2026, the company recorded order intake of €30.7 million. Including the repeat order exceeding €37 million announced on July 7, 2026, cumulative order intake since the beginning of the year amounts to €81.6 million.
- The order backlog stood at €54.8 million at the end of the quarter.
- For the full-year 2026 management maintains the guidance of more than €100 million revenues and EBITDA margin of more than 12%.
- In light of the sustained improvement in order momentum and enhanced business visibility, management has decided to increase its full-year 2026 order intake guidance from approximately €114 million to a range of €125 to €150 million.
More on SCHMID Group N.V.
- Schmid Group: AI Sales Are Growing, But Shareholders Might Be The Ones Paying For It
- SCHMID Group N.V. (SHMD) Q4 2025 Earnings Call Transcript
- SCHMID Group N.V. 2025 Q4 - Results - Earnings Call Presentation
- SCHMID Group to raise $20M through convertible notes
- SCHMID books €26M in advanced PCB orders as AI infrastructure spending accelerates
推薦文章
港股周報 | 黃金股狂飆！靈寶黃金周升24%；段永平「被動減持」泡泡瑪特；藥明康德升近20%創新高
一周財經日曆 | 重磅財報周！騰訊、Lumentum、中芯國際輪番登場！美國7月CPI攜零售數據來襲
8月8日外盤頭條：伊朗內部辯論霍爾木茲協議措辭 非農爆冷削弱加息預期 SpaceX將自建發電廠保障電力供應
Palantir股價將創下自2024年以來最佳單周表現，該股已不再是AI領域的失意者
7月非農就業數據走弱，支持美聯儲維持利率不變，但加息選項並未徹底排除
美股前瞻 | 聚焦20：30！市場靜候7月非農數據；特朗普政府擬加碼佈局關鍵礦產；應用光電計劃大規模擴產，光通信盤前集體飆升
港股異動 | 創新葯概念再度走強，再鼎新葯勁升14%，Q2產品收入環比增長11%；藥明生物升逾5%，百濟神州升逾3%
港股異動 | AI硬件股多數上漲，建滔積層板、勝宏科技漲逾5%，兆易創新漲逾3%；南方兩倍做多海力士跌逾9%
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
